Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

By Michael Erman and Mariam Sunny Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street ...